Hepatocellular carcinoma(HCC) is a highly aggressive malignant disease,with a poor clinical prognosis.Many standard therapies are often considered for HCC treatment today; however,these conventional therapies often fa...Hepatocellular carcinoma(HCC) is a highly aggressive malignant disease,with a poor clinical prognosis.Many standard therapies are often considered for HCC treatment today; however,these conventional therapies often fail to achieve sufficiently effective clinical results.Today,HCC therapy is set to undergo a major revolution,owing to rapid developments in cancer immunotherapy,particularly immune checkpoint inhibitor therapy.Cancer immunotherapy is a novel and promising treatment strategy that differs significantly from conventional therapies in its approach to achieve antitumor effects.In fact,many cancer immunotherapies have been tested worldwide and shown to be effective against various types of cancer; HCC is no exception to this trend.For example,we identified a specific cancer antigen called glypican-3(GPC3) and performed clinical trials of GPC3-targeted peptide vaccine immunotherapy in patients with HCC.Here,we present an overview of the immune mechanisms for development and progression of HCC,our GPC3-based immunotherapy,and immune checkpoint inhibitor therapy against HCC.Finally,we discuss the future prospects of cancer immunotherapy against HCC.We believe that this review and discussion of cancer immunotherapy against HCC could stimulate more interest in this promising strategy for cancer therapy and help in its further development.展开更多
文摘Hepatocellular carcinoma(HCC) is a highly aggressive malignant disease,with a poor clinical prognosis.Many standard therapies are often considered for HCC treatment today; however,these conventional therapies often fail to achieve sufficiently effective clinical results.Today,HCC therapy is set to undergo a major revolution,owing to rapid developments in cancer immunotherapy,particularly immune checkpoint inhibitor therapy.Cancer immunotherapy is a novel and promising treatment strategy that differs significantly from conventional therapies in its approach to achieve antitumor effects.In fact,many cancer immunotherapies have been tested worldwide and shown to be effective against various types of cancer; HCC is no exception to this trend.For example,we identified a specific cancer antigen called glypican-3(GPC3) and performed clinical trials of GPC3-targeted peptide vaccine immunotherapy in patients with HCC.Here,we present an overview of the immune mechanisms for development and progression of HCC,our GPC3-based immunotherapy,and immune checkpoint inhibitor therapy against HCC.Finally,we discuss the future prospects of cancer immunotherapy against HCC.We believe that this review and discussion of cancer immunotherapy against HCC could stimulate more interest in this promising strategy for cancer therapy and help in its further development.
